BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Analyst Ratings
NASDAQ:BCRX • US09058V1035
7.775 USD
+0.23 (+2.98%)
Last: Feb 26, 2026, 11:31 AM
ChartMill assigns a Buy % Consensus number of 85% to BCRX. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 22.21. This target is 185.7% above the current price.
- BCRX was analyzed by 15 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about BCRX.
- In the previous month the buy percentage consensus was at a similar level.
- BCRX was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-05 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-04 | Needham | Maintains | Buy -> Buy |
| 2025-11-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-15 | TD Cowen | Reiterate | Buy |
| 2025-10-15 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-15 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-10-15 | Needham | Maintains | Buy -> Buy |
| 2025-08-04 | Needham | Maintains | Buy -> Buy |
| 2025-07-01 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-30 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-06-30 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-06-27 | Needham | Reiterate | Buy -> Buy |
| 2025-06-25 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-06 | Needham | Maintains | Buy -> Buy |
| 2025-05-06 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-04-11 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-03-03 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-25 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-25 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-02-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-31 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-01-13 | Needham | Maintains | Buy -> Buy |
| 2025-01-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
What do analysts expect the price target to be for BIOCRYST PHARMACEUTICALS INC (BCRX)?
15 analysts have analysed BCRX and the average price target is 22.21 USD. This implies a price increase of 185.7% is expected in the next year compared to the current price of 7.775.
Can you provide the consensus rating for BIOCRYST PHARMACEUTICALS INC stock?
The consensus rating for BIOCRYST PHARMACEUTICALS INC (BCRX) is 85.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.